Immunotherapy has become one of the most promising avenues for cancer treatment, making use of the patient’s own immune system to eliminate cancer cells. Activated T cells are capable of directly recognizing antigens that are presented on the surfaces of tumour cells.Thus emerging immuno therapy technologies are now targeting activated T cells in order to identify and kill tumor cells.
The activation of T-cell immunity is primarily driven by the interaction between peptides presented by major histocompatibility complexes (pMHCs) and T-cell receptors (TCRs).TCRs are found on the surface of T-cells where they recognize protein fragments, named antigens, when these are presented by the MHC on the cell surface of antigen presenting cells.The TCR-pMHC complex consists of two components, namely the TCR and the pMHC. The MHC class I molecule is a heterodimeric glycoprotein that consists of an α chain and a β2-microglobulin chain. The α chain is composed of three globular domains named α1, α2 and α3 which are highly polymorphic, allowing the MHC variants to accommodate a diverse range of peptides of different lengths and compositions.
we are offering various pMHC complex recombinant molecules to be used in imuunotherapeutic research involving activation of T cells. These pMHC recombinants may be used in T cell screening, T cell activation in the development and characterization of tumor targeting T cells.
